PARP1 and nonpapillary renal cell carcinoma: It has been well documented that PARP inhibitor treatment enhances the anticancer effect of TKIs.[30, 31] Thus, we investigated whether HDAC8 inhibitors (such as PCI‐34051) modulate the sensitivity of ccRCC cells to TKIs.